A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

ClinicalTrials.gov Identifier:

NCT00091442

First received: September 8, 2004

Last updated: March 21, 2013

Last verified: March 2013

History of Changes

Results First Received: December 15, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Breast Cancer
Interventions:	Drug: Docetaxel Drug: DOXIL

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A total of 751 participants were enrolled and randomized at 143 sites in 19 countries.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
751 participants were randomly assigned to 2 treatment groups (Docetaxel: 373 ; DOXIL+docetaxel: 378). 750 participants received treatment (Docetaxel: 373; DOXIL+docetaxel: 377). 1 participant in DOXIL+docetaxel treatment group did not receive treatment.

Reporting Groups

	Description
Docetaxel	Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
DOXIL+Docetaxel	DOXIL and docetaxel combination: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.

Participant Flow: Overall Study

	Docetaxel	DOXIL+Docetaxel
STARTED	373	378
COMPLETED	4 ^[1]	5 ^[1]
NOT COMPLETED	369	373
Progressive Disease	220	189
Physician Decision	61	58
Withdrawal by Subject	38	46
Adverse Event	29	48
2cycles therapy beyond Complete response	9	16
Death	9	7
Lost to Follow-up	1	3
Not Specified	2	6

[1]	Indicates number of participants on study treatment at time of the primary objective

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Docetaxel	Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
DOXIL+Docetaxel	DOXIL and docetaxel combination: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Total	Total of all reporting groups

Baseline Measures

	Docetaxel	DOXIL+Docetaxel	Total
Number of Participants [units: participants]	373	378	751
Age [units: years] Mean ± Standard Deviation	52.0 ± 9.23	52.8 ± 9.17	52.4 ± 9.20
Gender [units: Participants]
Female	373	378	751
Male	0	0	0

Outcome Measures

Show All Outcome Measures

1. Primary:

Time to Progression [ Time Frame: From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled ]

Show Outcome Measure 1

2. Secondary:

Overall Survival [ Time Frame: From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled ]

Show Outcome Measure 2

3. Secondary:

Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR) [ Time Frame: Up to 30 to 42 days after last dose of study medication ]

Show Outcome Measure 3

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	From first dose of study medication until 30 days after the last dose of study medication.
Additional Description	751 participants were randomly assigned to 2 treatment groups (Docetaxel: 373 ; DOXIL+docetaxel: 378). 750 participants received treatment (Docetaxel: 373; DOXIL+docetaxel: 377). 1 participant in DOXIL+docetaxel treatment group did not receive treatment.

Reporting Groups

	Description
Docetaxel	Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
DOXIL+Docetaxel	DOXIL and docetaxel combination: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.

Serious Adverse Events

	Docetaxel	DOXIL+Docetaxel
Total, serious adverse events
# participants affected / at risk	59/373 (15.82%)	69/377 (18.30%)
Blood and lymphatic system disorders
Neutropenia ^{† 1}
# participants affected / at risk	14/373 (3.75%)	17/377 (4.51%)
Febrile neutropenia ^{† 1}
# participants affected / at risk	10/373 (2.68%)	10/377 (2.65%)
Leukopenia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	4/377 (1.06%)
Anaemia ^{† 1}
# participants affected / at risk	2/373 (0.54%)	2/377 (0.53%)
Lymphadenopathy ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Neutropenia ^{† 1}
# participants affected / at risk	14/373 (3.75%)	17/377 (4.51%)
Febrile neutropenia ^{† 1}
# participants affected / at risk	10/373 (2.68%)	10/377 (2.65%)
Leukopenia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	4/377 (1.06%)
Anaemia ^{† 1}
# participants affected / at risk	2/373 (0.54%)	2/377 (0.53%)
Lymphadenopathy ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Cardiac disorders
cardiac failure ^{† 1}
# participants affected / at risk	2/373 (0.54%)	1/377 (0.27%)
Atrial fibrillation ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Pericardial effusion ^{† 1}
# participants affected / at risk	2/373 (0.54%)	0/377 (0.00%)
Cardiac failure congestive ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cardiomyopathy ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Supraventricular tachycardia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Tachycardia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Diabetic ketoacidosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
cardiac failure ^{† 1}
# participants affected / at risk	2/373 (0.54%)	1/377 (0.27%)
Atrial fibrillation ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Pericardial effusion ^{† 1}
# participants affected / at risk	2/373 (0.54%)	0/377 (0.00%)
Cardiac failure congestive ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cardiomyopathy ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Supraventricular tachycardia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Tachycardia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Diabetic ketoacidosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Gastrointestinal disorders
Vomiting ^{† 1}
# participants affected / at risk	3/373 (0.80%)	4/377 (1.06%)
Diarrhoea ^{† 1}
# participants affected / at risk	2/373 (0.54%)	3/377 (0.80%)
Nausea ^{† 1}
# participants affected / at risk	3/373 (0.80%)	2/377 (0.53%)
Stomatitis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	4/377 (1.06%)
Abdominal pain ^{† 1}
# participants affected / at risk	2/373 (0.54%)	0/377 (0.00%)
Abdominal mass ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Dysphagia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Gastric haemorrhage ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Gastrointestinal ulcer ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Ileus ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Intestinal ischaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Peritonitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Vomiting ^{† 1}
# participants affected / at risk	3/373 (0.80%)	4/377 (1.06%)
Diarrhoea ^{† 1}
# participants affected / at risk	2/373 (0.54%)	3/377 (0.80%)
Nausea ^{† 1}
# participants affected / at risk	3/373 (0.80%)	2/377 (0.53%)
Stomatitis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	4/377 (1.06%)
Abdominal pain ^{† 1}
# participants affected / at risk	2/373 (0.54%)	0/377 (0.00%)
Abdominal mass ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Dysphagia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Gastric haemorrhage ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Gastrointestinal ulcer ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Ileus ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Intestinal ischaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Peritonitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
General disorders
Pyrexia ^{† 1}
# participants affected / at risk	3/373 (0.80%)	6/377 (1.59%)
Asthenia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	3/377 (0.80%)
Infusion related reaction ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Death ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Multi-organ failure ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Pyrexia ^{† 1}
# participants affected / at risk	3/373 (0.80%)	6/377 (1.59%)
Asthenia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	3/377 (0.80%)
Infusion related reaction ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Death ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Multi-organ failure ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hepatobiliary disorders
Biliary colic ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cholecystitis acute ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cholelithiasis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hyperbilirubinaemia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Biliary colic ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cholecystitis acute ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cholelithiasis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hyperbilirubinaemia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Immune system disorders
Anaphylactic reaction ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Anaphylactic reaction ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Infections and infestations
Pneumonia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	12/377 (3.18%)
Neutropenic sepsis ^{† 1}
# participants affected / at risk	4/373 (1.07%)	0/377 (0.00%)
Cellulitis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	2/377 (0.53%)
Urinary tract infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Appendicitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Breast abscess ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Catheter related infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Catheter site cellulitis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cystitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Erysipelas ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Folliculitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Groin abscess ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Lung infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pulpitis dental ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pyelonephritis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Skin infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Staphylococcal infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Subcutaneous abscess ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Tooth abscess ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Vaginal infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Viral infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Vulvitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Pneumonia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	12/377 (3.18%)
Neutropenic sepsis ^{† 1}
# participants affected / at risk	4/373 (1.07%)	0/377 (0.00%)
Cellulitis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	2/377 (0.53%)
Urinary tract infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Appendicitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Breast abscess ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Catheter related infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Catheter site cellulitis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Cystitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Erysipelas ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Folliculitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Groin abscess ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Lung infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pulpitis dental ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pyelonephritis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Skin infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Staphylococcal infection ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Subcutaneous abscess ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Tooth abscess ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Vaginal infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Viral infection ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Vulvitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Injury, poisoning and procedural complications
Fall ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Alcohol poisoning ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Humerus fracture ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Upper limb fracture ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Fall ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Alcohol poisoning ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Humerus fracture ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Upper limb fracture ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Investigations
Alanine aminotransferease increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Aspartate aminotransferase increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Blood creatinine increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Blood urea increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Ejection fraction decreased ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Alanine aminotransferease increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Aspartate aminotransferase increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Blood creatinine increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Blood urea increased ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Ejection fraction decreased ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Metabolism and nutrition disorders
Dehydration ^{† 1}
# participants affected / at risk	3/373 (0.80%)	2/377 (0.53%)
Hypocalcaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Hypokalaemia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Hypercalcaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hyperglycaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hypomagnesaemia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Dehydration ^{† 1}
# participants affected / at risk	3/373 (0.80%)	2/377 (0.53%)
Hypocalcaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Hypokalaemia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Hypercalcaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hyperglycaemia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hypomagnesaemia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Musculoskeletal and connective tissue disorders
Back pain ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Bone pain ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pathological fracture ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Back pain ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Bone pain ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pathological fracture ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Metastasis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Neoplasm malignant ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Adenocarcinoma ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Metastasis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Neoplasm malignant ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Nervous system disorders
Convulsion ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Heachache ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Loss of consciousness ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Brain stem syndrome ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Cerebrovascular accident ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Dizziness ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Grand mal convulsion ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hemiplegia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Speech disorder ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Syncope ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Convulsion ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Heachache ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Loss of consciousness ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Brain stem syndrome ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Cerebrovascular accident ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Dizziness ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Grand mal convulsion ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hemiplegia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Speech disorder ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Syncope ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Psychiatric disorders
Anxiety ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Mental status changes ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Anxiety ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Mental status changes ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Reproductive system and breast disorders
Metrorrhagia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Uterine polyp ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Metrorrhagia ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Uterine polyp ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Respiratory, thoracic and mediastinal disorders
Pleural effusion ^{† 1}
# participants affected / at risk	4/373 (1.07%)	0/377 (0.00%)
Pulmonary embolism ^{† 1}
# participants affected / at risk	2/373 (0.54%)	2/377 (0.53%)
Dyspnoea ^{† 1}
# participants affected / at risk	2/373 (0.54%)	1/377 (0.27%)
Acute respiratory failure ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Respiratory arrest ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Respiratory failure ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Asthma ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Asthmatic crisis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Bronchial haemorrhage ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Bronchospasm ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hydrothorax ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Hypoxia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Pneumothorax ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pulmonary oedema ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Pleural effusion ^{† 1}
# participants affected / at risk	4/373 (1.07%)	0/377 (0.00%)
Pulmonary embolism ^{† 1}
# participants affected / at risk	2/373 (0.54%)	2/377 (0.53%)
Dyspnoea ^{† 1}
# participants affected / at risk	2/373 (0.54%)	1/377 (0.27%)
Acute respiratory failure ^{† 1}
# participants affected / at risk	1/373 (0.27%)	1/377 (0.27%)
Respiratory arrest ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Respiratory failure ^{† 1}
# participants affected / at risk	0/373 (0.00%)	2/377 (0.53%)
Asthma ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Asthmatic crisis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Bronchial haemorrhage ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Bronchospasm ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Hydrothorax ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Hypoxia ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Pneumothorax ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Pulmonary oedema ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome ^{† 1}
# participants affected / at risk	0/373 (0.00%)	7/377 (1.86%)
Intertrigo ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Palmar-plantar erythrodysaesthesia syndrome ^{† 1}
# participants affected / at risk	0/373 (0.00%)	7/377 (1.86%)
Intertrigo ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Surgical and medical procedures
Surgery ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Uterine dilation and curettage ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Surgery ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Uterine dilation and curettage ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Vascular disorders
Deep vein thrombosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Embolism ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Hypertension ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Jugular vein thrombosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Phlebitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Subclavian vein thrombosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Superior vena caval occlusion ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Deep vein thrombosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Embolism ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Hypertension ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Jugular vein thrombosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Phlebitis ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)
Subclavian vein thrombosis ^{† 1}
# participants affected / at risk	1/373 (0.27%)	0/377 (0.00%)
Superior vena caval occlusion ^{† 1}
# participants affected / at risk	0/373 (0.00%)	1/377 (0.27%)

†	Events were collected by systematic assessment
1	Term from vocabulary, MedDRA 10.0

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission. Expedited reviews will be arranged if needed. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application. The sponsor will not mandate modifications to scientific content and does not have the right to suppress information.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Director Medical Leader
Organization: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
phone: 908 218 7361 ext NA

No publications provided

Responsible Party:	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:	NCT00091442 History of Changes
Obsolete Identifiers:	NCT00343538
Other Study ID Numbers:	CR004120, DOXILBCA3001
Study First Received:	September 8, 2004
Results First Received:	December 15, 2009
Last Updated:	March 21, 2013
Health Authority:	United States: Food and Drug Administration Ukraine: State Pharmacological Center - Ministry of Health

To Top